Navigation Links
Cannabis Science (CBIS) Moves Forward with Critical Support of Landmark Federal Cannabis Legislative Initiative
Date:12/2/2013

COLORADO SPRINGS, Colo., Dec. 2, 2013 /PRNewswire/ -- (NASDAQ OTC: CBIS) Cannabis Science, Inc., a U.S. Company specializing in cannabis formulation-based drug development, is a key leader in the private sector challenge to end the restrictions on cannabis drug development and research in the U.S.  "The Cannabinoid Scientific Research and Development Act," which will be submitted for congressional review in the U.S. Senate and House of Representatives by the end of January 2014, is landmark legislation seeking equal treatment for cannabinoid scientific research.  In addition, the legislation aims to provide the framework for the clinical investigation of the hundreds of strains of cannabis and their constituent cannabinoids regarding their medical efficacy on a wide range of life-threatening, chronic, and infectious diseases. 

The legislation also seeks to provide "an informed clinical environment for physicians, researchers and consumers to make effective clinical choices regarding their therapeutic treatments for a variety of diseases," said Dr. Robert Melamede, President, Cannabis Science.  "We need rational federal standards based upon science to replace inadequate public policies rooted in the misperceptions of the past," Dr. Melamede added.

The legislation directs the U.S. Secretary of Health and Human Services to develop guidelines, standards, and regulations that provide the framework for development of cannabis research.  It also asks that this new regulatory framework begin rapidly after the removal of legal and regulatory obstacles for that research and that these guidelines follow a milestone 2007 Drug Enforcement Administrative Law ruling overturning the prejudicial procedures that effectively disallow domestic cannabis research and drug development.

Cannabis Science views these federal legislative developments as a critical part of the growth and development of its domestic biotechnology business.  "We need the same consideration in terms of the ability to conduct clinical trials and to develop therapies as other firms in the biotechnology sector," said Dr. Dorothy Bray, CEO of Cannabis Science.  Dr. Bray continued, "We also need to level the playing field to match rapidly changing regulatory environment in other countries that either have or are accommodating cannabis research."

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and HIV related cancers such as Kaposi's sarcoma.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Cannabis Science, Inc.
Dr. Dorothy Bray, CEO & Director
www.cannabisscience.com

Investment Inquiries
Robert Kane, CFO & Director
rkane@cannabisscience.com
561.420.4824


'/>"/>
SOURCE Cannabis Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. GrowLife Debuts First Kiosk-Based Payment, Cash Management, and Regulatory Compliance Technology for Legal Cannabis Dispensaries
2. Cannabis Science Announces The Depository Trust Company (DTC) Lifts Share Trading "Chill" Effective Immediately
3. X-Change Corp. Delighted with DOJs Historic Shift Toward Non-Interference Within State Cannabis Regulatory Environments; Sees Green Light for Companys Patient-Driven Medical Cannabis Operations Under State Laws
4. X-Change Corporation Signs Multi-Million Dollar Agreement for Multi-State Product Release Licensing, Medical Cannabis Dispensary Management, and Cultivation Consulting
5. American Drug War II: Cannabis Destiny is IMDBs Highest Rated 2013 Documentary
6. Cannabis Science Appoints Clinical Development Expert, Dr. Dorothy Bray, as Chief Executive Officer (CEO) and Director, Focusing on CS-TATI-1 and Building Companys Drug Development Pipeline
7. Virogens New Business Unit, "The Cannabis Connection," to Focus on High-End Medicinal Marijuana Dispensary Niche within $15-20 Billion Legal Marijuana Market
8. Virogen Announces Launch of New Business Unit, "The Cannabis Connection", and Sets Sights on $15-20 Billion Legal Marijuana Market
9. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
10. Abattis Provides $10,000 Sponsorship to the American Herbal Pharmacopoeia for Cannabis Monograph Project
11. Optimism of Cannabis Patients Creates More Demand for Phytiva Brand of Cannabinoid Solutions as Illinois and New Hampshire Take Key Legislative Steps Toward Legalization of Medical Cannabis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... March 23, 2017 As a result ... with the prevalence of allergic diseases, cutting edge ... currently revolutionising the ways in which pharmaceutical and ... 2017 promises to be both a high quality ... allergy interest groups, immunologists, research scholars and doctors. ...
(Date:3/23/2017)... 23, 2017   BioSpace , the leading biotechnology ... with Indiana Biosciences Research Institute and over ... educational institutions to bring the state,s life sciences industry ... map, an artistic representation of the region,s booming biotechnology ... Vice President Mike Pence , a long-time advocate ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... VA (PRWEB) , ... March 24, 2017 , ... The ... 2017 Quest Awards . The annual awards, now in their 12th year, are ... peers selects the winners. , In 2016, the awards were retooled to recognize achievements ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
(Date:3/24/2017)... Miami, FL (PRWEB) , ... March 24, 2017 ... ... HyGIeaCare Inc. ( http://www.hygieacare.com ) announced their partnership to prep patients for colonoscopy ... Health Endoscopy Centers in 87th Ave., Miami, FL. , The ...
Breaking Medicine News(10 mins):